| Siliq (brodalumab) / Bausch Health |
2018-000097-30: Efficacy of brodalumab in patients with psoriasis with failure of other anti-IL-17 treatments Effekt af brodalumab hos patienter, som har haft svigt af anti-IL-17A-behandling |
|
|
| Ongoing | 4 | 20 | Europe | brodalumab, Solution for injection in pre-filled syringe, Kyntheum | Herlev and Gentofte Hospital, LEO Pharma A/S | Psoriasis Psoriasis, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2018-001021-10: A Clinical study with brodalumab for patients suffering from psoriasis and not benefitting the TNF-alpha treatment. |
|
|
| Ongoing | 4 | 90 | Europe | Injection, Kyntheum | Sahlgrenska University Hospital, Leo Pharma Ab | Moderate to severe plaque psoriasis, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis |
|
|
| Not yet recruiting | 4 | 244 | Europe | secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya | Radboudumc, ZonMw, KCE | psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-003785-13: Trial to investigate efficacy of brodalumab in eczematized psoriasis |
|
|
| Not yet recruiting | 4 | 15 | Europe | Brodalumab, Injection, Brodalumab | Karolinska Universitetssjukhuset, Leo Pharma | eczematized psoriasis, Psoriasis with eczema like features, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 4 | 10 | NA | Brodalumab | First OC Dermatology | Palmoplantar Psoriasis | 11/21 | 05/22 | | |
| Active, not recruiting | 4 | 244 | Europe | Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent | Psoriasis, Psoriasis Vulgaris | 12/25 | 12/25 | | |
ChiCTR2000039699: A Phase 4 Clinical Study to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy of Brodalumab (KHK4827) in Subjects with Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 4 | 400 | | Brodalumab Injection (KHK4827) 210 mg Q2W ;Placebo | Peking University People's Hospital; Kyowa Kirin Co., Ltd., self financing | The treatment of moderate to severe Plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy | | | | |
NCT03240809: An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects |
|
|
| Recruiting | 4 | 16 | US | Brodalumab | Bausch Health Americas, Inc. | Psoriasis | 07/24 | 07/24 | | |
| Recruiting | 4 | 384 | Europe, RoW | Brodalumab | LEO Pharma, LEO Pharma A/S | Psoriasis Vulgaris | 09/25 | 01/26 | | |
NCT03957681: A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis |
|
|
| Active, not recruiting | 3 | 100 | Japan | KHK4827, Placebo | Kyowa Kirin Co., Ltd. | Moderate to Severe Systemic Sclerosis | 10/20 | 02/24 | | |
|
NCT04061252: A Study of KHK4827 in Subjects With Palmoplantar Pustulosis |
|
|
| Completed | 3 | 126 | Japan | KHK4827, Placebo | Kyowa Kirin Co., Ltd. | Palmoplantar Pustulosis | 08/21 | 08/22 | | |
| Terminated | 3 | 12 | Europe | Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo | LEO Pharma | Psoriasis | 05/23 | 05/23 | | |
NCT04368403: A Study of KHK4827 in Patients With Systemic Sclerosis |
|
|
| Active, not recruiting | 1 | 8 | Japan | KHK4827 | Kyowa Kirin Co., Ltd. | Systemic Sclerosis | 01/19 | 02/24 | | |
| Not yet recruiting | N/A | 15 | NA | Fecal sample collection | Association pour la Recherche Clinique et Immunologique | Psoriasis | 01/22 | 01/22 | | |
| Recruiting | N/A | 100 | Europe | Venapuncture, Patient questionnaires | University Hospital, Ghent, KU Leuven, University Ghent | Psoriasis Vulgaris | 12/24 | 12/24 | | |
CARE, NCT05132231: Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity |
|
|
| Recruiting | N/A | 500 | Canada | Brodalumab, Matched cohort | Bausch Health Americas, Inc. | Psoriasis | 06/24 | 06/24 | | |
NCT03358693: Molecular Signatures in Inflammatory Skin Disease |
|
|
| Recruiting | N/A | 300 | Europe | Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis, Psoriasis | 12/27 | 12/28 | | |
NCT03254667: LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis |
|
|
| Enrolling by invitation | N/A | 3500 | US | Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors) | Bausch Health Americas, Inc. | Psoriasis | 11/30 | 11/31 | | |